- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00593983
Peer-Driven Intervention to Enroll Minorities/Women in HIV/AIDS Clinical Trials (the ACT2 Project)
Peer-Driven Intervention to Enroll Minorities/Women in HIV/AIDS Clinical Trials
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
According to a 2001 report by the U.S. Census Bureau, African Americans and Latinos make up 65% of all AIDS cases reported in the United States, yet they make up only 25% of the population in the United States. In addition, the number of women living with HIV/AIDS, many of whom are minorities, is rapidly increasing. ACTs are research studies designed to evaluate new therapies to fight HIV infection and prevent and treat opportunistic infections and cancers associated with AIDS. Preliminary research suggests that intensive intervention efforts are needed to improve rates of screening and to enroll more racial/ethnic minorities and women in ACTs. The purpose of this study is to identify effective intervention strategies to increase the low number of HIV infected racial/ethnic minorities and women who are screened for and enrolled into ACTs.
Each participant will be enrolled in the study for 12 months. Participants will be randomly assigned to either the intervention or control arm. Initial "seed" participants in the intervention arm will complete a peer-driven intervention consisting of four structured intervention sessions lasting 6 hours in total (occurring every week for 4 weeks), three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening. Participants in the control arm will complete a time-matched health education intervention lasting 6 hours. Participants in the control arm will also receive the community standard of care and be referred to their local ACT unit. Peer participants will be recruited by either a seed or through general recruitment; those recruited by an initial seed will participate in the same arm as the see d who recruited them. Study visits will occur throughout the study. Participants in the intervention arm will complete an interview at Week 30. At Weeks 8, 16 and 52, all participants will complete social impact assessments. At Weeks 16 and 52, all participants will complete follow-up visits.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria for Initial Seeds:
- HIV infected
- Seen at the Betances Health Center or AIDS Service Center at least once in the last 6 months prior to study entry
- Of African-American or Latino descent
- Willing to recruit HIV infected peers
- Able to conduct research activities (e.g., speaking and writing when necessary) in English
Inclusion Criteria for Peers:
- Documented recruitment for study participation
- HIV infected
- Willing to recruit HIV infected peers
- Able to conduct research activities (e.g., speaking and writing when necessary) in English
Exclusion Criteria:
- Currently enrolled in an HIV/AIDS clinical trial
- Currently psychotic based on standard assessment (e.g., MINI, Lecrubier et al., 1997)
- Any condition that, in the opinion of the investigator, would interfere with participation in the study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: 1
|
Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
|
|
Comparador de placebos: 2
Control
|
Health education and standard of care treatment
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Participation in screening for AIDS clinical trials to the point of determining eligibility, coded as yes/no.
Periodo de tiempo: within the participant's 52 week follow up period
|
During interventions, participants in both arms receive contact information for local AIDS clinical trials units.
Two sources of data are used to determine whether screening occurred.
First, for participants screened at Beth Israel Medical Center, the study's main collaborating site, the screener notes the screening event in a participant status file.
Second, during follow-up interviews at 16 and 52 weeks post-baseline, participants' screening experiences at other units are assessed.
This self-reported screening is confirmed with the clinical trials units (all screening reports are verified).
|
within the participant's 52 week follow up period
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Enrollment into an AIDS clinical trial or HIV/AIDS biomedical research study
Periodo de tiempo: within the participant's 52 week follow-up period
|
Two sources of data are used to determine whether enrollment occurred.
First, for participants screened at Beth Israel Medical Center, the study's main collaborating site, study staff confirms participation in the trial with participants and trials units and log this in a participant status file.
Second, during follow-up interviews at 16 and 52 weeks post-baseline, enrollment in studies and trials is assessed.
This self-reported enrollment is confirmed with the clinical trials units (all enrollment reports are verified).
|
within the participant's 52 week follow-up period
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Marya Gwadz, PhD, New York University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Infecciones por VIH
Otros números de identificación del estudio
- ACT2
- R01AI070005 (Subvención/contrato del NIH de EE. UU.)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .